Articles tagged with Tissue Plasminogen Activator
Researchers found that hospitals that implemented standardized protocols from the American Heart Association and American Stroke Association saw significant reductions in stroke treatment times. The protocols, which include specific limits on time between symptom onset and hospital arrival, helped medical teams respond more quickly to ...
Researchers investigated the effectiveness of systemic thrombolysis for acute portal vein thrombosis (PVT) in liver cirrhosis patients. After a 7-day treatment period, 60% of patients achieved full recanalization of the portal vein, with no significant side effects.
Scientists at Texas A&M University found that transplanting intestinal epithelial stem cells can repair the gut and reduce inflammation, potentially preserving cognitive function after a stroke. The study suggests that targeting gut health may be key to developing more effective stroke therapies.
Researchers at Keck School of Medicine of USC are testing the efficacy of 3K3A-APC as a cerebroprotectant to reduce brain bleeds in acute ischemic stroke patients. The experimental drug has shown promising results in Phase 2 clinical trials, reducing incidence of brain hemorrhage by nearly 20%.
Patients treated by mobile stroke units had faster anti-clot medication delivery and less disability at 90 days compared to standard ambulance care, according to a study published in NEJM. The trial, which enrolled over 1,500 patients, showed that MSU-treated patients were more likely to receive tPA and have better mortality rates.
Mobile devices have been found to be both reliable and accurate for making clinical decisions about administering IV thrombolysis in patients with acute stroke. This allows for increased neuroradiologist availability and the potential use of reperfusion therapies in resource-limited countries.
A meta-analysis of severe frostbite injuries found promising results using intraarterial and intravenous tissue plasminogen activator to reduce amputation rates. The study included 209 patients treated with thrombolytic therapy, resulting in a salvage rate of 76%.
Mice deficient in tPA exhibited greater white matter damage and cognitive function loss after TBI, while tPA treatment improved neurological function. The study suggests a potential therapeutic target for recovering from TBI.
Researchers developed a new test combining International Normalized Ratio and thrombelastography to predict massive transfusion needs in trauma patients. The test was found to be highly sensitive and specific, reducing unnecessary transfusions by 97%.
A study found that retigabine, an epilepsy drug, protected the brain against ischemic stroke damage in mouse models. The medication acted directly on nerve cells to minimize damage, showing protective effects up to five days after the stroke.
A study published in Neural Regeneration Research found that pro-urokinase is more effective than urokinase in dissolving blood clots and promoting angiogenesis. However, it did not reduce neuronal apoptosis after acute cerebral ischemia.
A clinical trial combining brain cooling and clot-busting drug therapy has received FDA approval to expand from 50 to 400 participants. Brain cooling has been shown to reduce neurological damage after stroke, with potential benefits in saving lives and preventing neurological damage after heart attack.
Research found that only 26.6% of acute stroke patients received intravenous tissue plasminogen activator (tPA) within 60 minutes of hospital arrival. Timely tPA administration was associated with lower in-hospital mortality and fewer complications.
Research suggests that patients with stroke experiencing improvement within one hour of receiving clot-dissolving medication are more likely to have favorable outcomes three months later. This improvement is associated with reduced risk of death and better recovery rates.
Patients admitted on weekends are 20% more likely to receive tissue plasminogen activator, a clot-dissolving medication. Despite this increased use, weekend stroke deaths do not differ significantly from weekday deaths.
Researchers found that four out of six patients treated with stents and tPA experienced permanent improvement in neurologic symptoms, while two critically ill patients died due to large clots. The study suggests a combined treatment approach may offer superior results for most patients with acute vertebrobasilar ischemic strokes.
A new study found that early t-PA treatment can have a long-lasting benefit for patients who experienced a stroke. Within three hours of symptoms onset, patients treated with tissue plasminogen activator (t-PA) were at least 30% more likely to have minimal or no disability at 12 months compared to placebo-treated patients.